Signore e Signori.... ecco a voi...:
Una volta tanto vi riporto qualcosa di interessante anch'io
Mixxx
[X]
---------------------------------------------------------------------
http://www.clinicaltrials.gov/ct2/show?term=neosh101&rank=1
---------------------------------------------------------------------
Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss
This study has been completed.
Sponsored by: Neosil, Inc.
Information provided by: Neosil, Inc.
ClinicalTrials.gov Identifier: NCT00418730
Purpose
The purpose of this study is to measure the hair growth response to topical NEOSH101 when applied twice daily to the balding scalp for 16 weeks. One hundred eighty men with Norwood/Hamilton grades III-IV with thinning in the top and center of the scalp will participate. Three equally sized treatment groups (60 men each) will receive either topical NEOSH101 2.0%, minoxidil 5%, or placebo.
Condition Intervention Phase
Androgenetic Alopecia
Drug: tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
Phase II
Genetics Home Reference related topics: Hair Diseases and Hair Loss
MedlinePlus related topics: Hair Diseases and Hair Loss
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Phase 2 Multicenter, Randomized, Placebo- and Comparator-Controlled, Double-Blind Parallel Group Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men
Further study details as provided by Neosil, Inc.:
Primary Outcome Measures:
Hair density, hair growth rate, hair diameter as measured using the TrichoScan method [ Time Frame: Through Study Day 197 ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
Assessment score of dermal tolerability [ Time Frame: Through Study Day 197 ] [ Designated as safety issue: Yes ]
Physician's global assessment score [ Time Frame: Through Study Day 197 ] [ Designated as safety issue: No ]
Enrollment: 180
Study Start Date: January 2007
Study Completion Date: April 2008
Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Experimental Drug: tetrapeptide aldehyde proteasome inhibitor
Una volta tanto vi riporto qualcosa di interessante anch'io
Mixxx
[X]
---------------------------------------------------------------------
http://www.clinicaltrials.gov/ct2/show?term=neosh101&rank=1
---------------------------------------------------------------------
Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss
This study has been completed.
Sponsored by: Neosil, Inc.
Information provided by: Neosil, Inc.
ClinicalTrials.gov Identifier: NCT00418730
Purpose
The purpose of this study is to measure the hair growth response to topical NEOSH101 when applied twice daily to the balding scalp for 16 weeks. One hundred eighty men with Norwood/Hamilton grades III-IV with thinning in the top and center of the scalp will participate. Three equally sized treatment groups (60 men each) will receive either topical NEOSH101 2.0%, minoxidil 5%, or placebo.
Condition Intervention Phase
Androgenetic Alopecia
Drug: tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
Phase II
Genetics Home Reference related topics: Hair Diseases and Hair Loss
MedlinePlus related topics: Hair Diseases and Hair Loss
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Phase 2 Multicenter, Randomized, Placebo- and Comparator-Controlled, Double-Blind Parallel Group Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men
Further study details as provided by Neosil, Inc.:
Primary Outcome Measures:
Hair density, hair growth rate, hair diameter as measured using the TrichoScan method [ Time Frame: Through Study Day 197 ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
Assessment score of dermal tolerability [ Time Frame: Through Study Day 197 ] [ Designated as safety issue: Yes ]
Physician's global assessment score [ Time Frame: Through Study Day 197 ] [ Designated as safety issue: No ]
Enrollment: 180
Study Start Date: January 2007
Study Completion Date: April 2008
Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Experimental Drug: tetrapeptide aldehyde proteasome inhibitor
